Glenmark and Teijin form respiratory collaboration
‘Glenmark Pharmaceuticals SA, the Swiss subsidiary of India’s Glenmark Pharmaceuticals, has signed a collaboration agreement with Japan’s Teijin Pharma Limited, a subsidiary of Teijin Limited, for a respiratory disorders product.
The two companies have entered into a collaboration agreement for Glenmark’s PDE4 inhibitor GRC 3886, which is currently in development for chronic obstructive pulmonary disorder (COPD) and asthma. The compound may also have utility in other inflammatory conditions such as rheumatoid arthritis.
PDE4 inhibitors target the underlying cause of both COPD and asthma by blocking inflammation through a non-steroid dependent mechanism. In preclinical trials, GRC 3886 was shown to be a highly specific PDE4 inhibitor with potential for the indications of asthma and COPD.
The phase I studies were conducted in the UK by Quintiles, a global contract research organization, and have recently been completed. The phase I studies have demonstrated that GRC 3886 is well tolerated and exhibits predictable pharmacokinetics in human volunteers. The molecule has been found to be non-emetic and without any apparent cardiovascular effects at the highest doses tested in the study.
Additionally, the drug has exhibited a long half-life, suggesting a once-daily-dosing regimen may be possible in future studies in patients. ‘
Read more at Glenmark and Teijin form respiratory collaboration
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax